ATM potentiator-1
ATM potentiators-1 is a quercetin derivative that synergistically enhances the antibacterial activity of Aztreonam (ATM, HY-B0129) against metallo-β-lactamase-producing Pseudomonas aeruginosa. ATM potentiators-1 inhibits NDM-1, OXA-10, VIM-2, KPC-2, and OXA-48, suppressing the efflux pump activity of Pseudomonas aeruginosa. When used in combination with CCCP (HY-100941), it exhibits a synergistic inhibitory effect. ATM potentiators-1 is applicable to research related to Pseudomonas aeruginosa infections.
For research use only. We do not sell to patients.
- Formula: C23H22F2N4O5
- Molecular Weight:472.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Beta-lactamase Isoforms
More
Biological Activity
Description
In Vitro
ATM potentiators-1 (compound 9) inhibits purified β-lactamases KPC-2, NDM-1, VIM-2, OXA-48, and OXA-10 with IC50 values ranging from 1.6 to 26.7 μM, with the strongest activity against NDM-1[1].
ATM potentiators-1 (0-50 μM; 10 min) binds to the active site of purified NDM-1, as shown by concentration-dependent quenching of intrinsic tryptophan fluorescence[1].
ATM potentiators-1 (8 mg/L; 60 min) inhibits efflux pumps in NDM-1-producing Pseudomonas aeruginosa strain PA-017, as indicated by enhanced intracellular retention of ethidium bromide[1].
ATM potentiators-1 (16 mg/L; 24 h) potentiates aztreonam activity against NDM-1-producing Pseudomonas aeruginosa strain PA-017[1].
ATM potentiators-1 (1-32 mg/L; 18-24 h) potentiates aztreonam activity against 29 carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa isolates, with 93% showing synergistic interaction (FICI ≤0.5) and a ≥4-fold reduction in aztreonam MIC[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Immortalized human embryonic kidney (HEK293) cells
-
Concentration:0.5, 1, 2, 4, 8, 16, 32 mg/L
-
Incubation Time:24 h
-
Result:Did not affect HEK293 cell viability at concentrations up to 32 mg/L.
Parmacokinetics
| Species | Dose | Route | T1/2 | Cmax | AUC0-last | AUC0-∞ | MRT0-last | MRT0-∞ | C0 | Vss | Vz | CL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 5 mg/kg | i.v. | 1.44 h | 6.96 mg/L | 2.55 mg·h/L | 2.61 mg·h/L | 0.63 h | 0.85 h | 13.23 mg/L | 3.45 L/kg | 1.00 L/kg | 2000 mL/h/kg |
In Vivo
ATM potentiators-1 (10-40 mg/kg; i.p.; single dose) is well-tolerated in 6 week-old female C57BL/6J mice, with 100% survival over 7 days[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (7 week-old female, 20-22 g, intramuscular thigh infection with NDM-1-producing Pseudomonas aeruginosa strain PA-017)[1]
-
Dosage:40 mg/kg (in combination with 20 mg/kg aztreonam)
-
Administration:i.p.; 4 total doses at 2-hour intervals
-
Result:Reduced mean bacterial burden in thigh tissue to 4.26 log10 CFU/thigh, representing a 3.4 log10 drop compared to untreated control.
Achieved a greater reduction than aztreonam alone (2.2 log10 drop).
Reduced thigh muscle weight by 26.4% compared to untreated control.
Caused no significant body weight changes or overt clinical signs.
-
Animal Model:C57BL/6J mice (6 week-old female)[1]
-
Dosage:10 mg/kg; 20 mg/kg; 40 mg/kg
-
Administration:i.p.; single dose
-
Result:Resulted in 100% survival of mice over the 7-day observation period for all doses.
Chemical Information
-
Molecular Weight 472.44
-
Formula C23H22F2N4O5
-
SMILES
OC1=C2C(C(OCCC(C)(C)C)=C(OC2=CC(OCC3=NN=NN3)=C1)C4=CC=C(C(F)=C4)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)